Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose almonertinib first-line treatment for EGFR L858R-mutated advanced lung adenocarcinoma
ChiCTR2500095661Phase 2Recruiting
- Sponsor
- Guangzhou Panyu District Central Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Guangzhou Panyu District Central Hospital. Primary endpoint: Progression-free survival. Started Jan 2025; status: recruiting.
02
Drugs
almonertinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500095661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095661.